Cybin (CYBN) Is Up 13.7% After Announcing Move To Nasdaq With New “HELP” Ticker

• Cybin Inc has announced it will shift its U.S. listing from NYSE American to the Nasdaq Global Market on January 5, 2026, adopting the ticker symbol “HELP” on both Nasdaq and Cboe Canada.
• This exchange move could broaden Cybin’s access to institutional investors and index inclusion, potentially increasing liquidity and awareness of its mental health pipeline.
• With Cybin’s recent share price gains, we’ll examine how the move to Nasdaq and new “HELP” ticker shape its investment narrative.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 25 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

What Is Cybin's Investment Narrative?

To own Cybin, you have to believe its psychedelic-based mental health drugs can translate promising mid-stage data into full approvals and, eventually, commercial revenue from a starting point of essentially zero sales and sizeable losses. The upcoming CYB004 Phase 2 data in generalized anxiety in early 2026 and the CYB003 PARADIGM program in depression remain the key value drivers in the near term, with financing needs and clinical risk still front and center after the recent CAD 175.01 million equity raise and ongoing net losses. The move to Nasdaq under the new “HELP” ticker looks more like a visibility and liquidity upgrade than a fundamental shift in those core catalysts or risks, and the recent share price bounce so far supports that view rather than re-rating the whole story.

However, Cybin’s heavy cash burn and recent dilution are things investors should be aware of. Cybin's shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six Simply Wall St Community fair value views, from about US$7.39 to US$73.95, show just how far apart investors can be, especially when clinical milestones, cash burn and dilution risk still dominate Cybin’s outlook.

Explore 6 other fair value estimates on Cybin - why the stock might be worth over 10x more than the current price!

Build Your Own Cybin Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Cybin research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
• Our free Cybin research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cybin's overall financial health at a glance.

No Opportunity In Cybin?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 35 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com